Source / episode info

• **Episode:**507
• **Title:**Divine Intervention Episode 507: The Clutch Sickle Cell Disease Podcast (for Step 1-3) Part 1
• **Published:**2024-01-30
• Source:Episode page

One-liner

This episode provides a comprehensive review of Sickle Cell Disease (SCD), covering its -globin gene mutation, the pathophysiology triggered by hypoxia and polymerization of HbS, associated complications (vaso-occlusion, hemolysis), prophylactic strategies for encapsulated organisms, and management with hydroxyurea.

High-yield summary

• Genetics: SCD is caused by a single base change in the -globin gene, substituting Glutamic acid for Valine at position 6, resulting in Hemoglobin S (HbS).
• Pathophysiology Trigger: The polymerization of HbS occurs primarily under conditions of hypoxia and dehydration, leading to sickling of red blood cells.
• Clinical Triad: Sickle cells cause three major problems: 1) Blood stasis -> risk of venous thrombosis; 2) Vessel occlusion -> ischemia/tissue death; 3) Hemolysis -> increased susceptibility to splenic damage.
• Prophylaxis (Primary Prevention): Newborns with SCD require prophylactic antibiotics for at least five years, targeting encapsulated organisms, most commonly Streptococcus pneumoniae.
• Management: The first-line treatment is Hydroxyurea, which increases the levels of protective Hemoglobin F (_2_2), thereby inhibiting HbS polymerization.
• Differential Diagnosis Clues: SCD + Beta Thalassemia presents with a microcytic, hyperchromic anemia AND abnormally elevated Hemoglobin A2 on electrophoresis.

Learning objectives

• Describe the molecular basis and polymerization trigger for Hemoglobin S in SCD.
• Outline the clinical manifestations resulting from chronic vaso-occlusion and hemolysis.
• Identify appropriate primary prevention strategies (antibiotics) and their targets in newborns with SCD.
• Explain the mechanism of action and indications for hydroxyurea therapy.
• Differentiate laboratory findings (electrophoresis, reticulocyte count, anemia type) between SCD, SCD + Thalassemia, and SCD Aplastic Crisis.